CA2625917A1 - Artificial platelets - Google Patents

Artificial platelets Download PDF

Info

Publication number
CA2625917A1
CA2625917A1 CA002625917A CA2625917A CA2625917A1 CA 2625917 A1 CA2625917 A1 CA 2625917A1 CA 002625917 A CA002625917 A CA 002625917A CA 2625917 A CA2625917 A CA 2625917A CA 2625917 A1 CA2625917 A1 CA 2625917A1
Authority
CA
Canada
Prior art keywords
peptide
fibrinogen
fibrinogen binding
precursor
wound site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002625917A
Other languages
English (en)
French (fr)
Inventor
Alison Helena Goodall
Sarah Margaret Taylor
Greg Francis Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Haemostatix Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2625917A1 publication Critical patent/CA2625917A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002625917A 2005-08-04 2006-08-04 Artificial platelets Abandoned CA2625917A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0516091.6A GB0516091D0 (en) 2005-08-04 2005-08-04 Therapeutic agent
GB0516091.6 2005-08-04
PCT/GB2006/002934 WO2007015107A2 (en) 2005-08-04 2006-08-04 Artificial platelets

Publications (1)

Publication Number Publication Date
CA2625917A1 true CA2625917A1 (en) 2007-02-08

Family

ID=34984119

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002625917A Abandoned CA2625917A1 (en) 2005-08-04 2006-08-04 Artificial platelets

Country Status (9)

Country Link
US (2) US20090203619A1 (cg-RX-API-DMAC10.html)
EP (2) EP2335737A3 (cg-RX-API-DMAC10.html)
JP (1) JP2009505964A (cg-RX-API-DMAC10.html)
CN (1) CN101267843A (cg-RX-API-DMAC10.html)
AU (1) AU2006274685A1 (cg-RX-API-DMAC10.html)
CA (1) CA2625917A1 (cg-RX-API-DMAC10.html)
GB (2) GB0516091D0 (cg-RX-API-DMAC10.html)
IL (1) IL189105A0 (cg-RX-API-DMAC10.html)
WO (1) WO2007015107A2 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623607D0 (en) 2006-11-27 2007-01-03 Haemostatix Ltd Tissue adhesive
WO2008113796A1 (en) * 2007-03-21 2008-09-25 Dsm Ip Assets B.V. Cholesterol lowering protein hydrolysates
KR20100057061A (ko) * 2007-09-11 2010-05-28 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드 ｍａｉｐｐｋｋｎｑｄｋ （소 카파 카세인 １０６－１１６）및／또는 ｙｇｆｑｎａ （세로르핀）의 용도
US20100204107A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of urodilatin as a therapeutic agent
GB201101740D0 (en) * 2011-02-01 2011-03-16 Haemostatix Ltd Therapeutic agents with improved fibrinogen binding
WO2013021353A1 (en) * 2011-08-11 2013-02-14 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
GB201201751D0 (en) * 2012-02-01 2012-03-14 Haemostatix Ltd Haemostatic wound dressing
WO2014197816A1 (en) * 2013-06-06 2014-12-11 Massachusetts Institute Of Technology Stimulus responsive nanocomplexes and methods of use thereof
KR20230007555A (ko) * 2013-06-28 2023-01-12 바이오버라티브 테라퓨틱스 인크. Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
EP3069141A4 (en) 2013-11-15 2017-05-10 President and Fellows of Harvard College Methods and assays for factor viii activity
GB201400292D0 (en) * 2014-01-08 2014-02-26 Haemostatix Ltd Peptide dendrimers and agents
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
GB201508024D0 (en) * 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions
CN107686506B (zh) * 2016-08-05 2021-03-30 首都医科大学 华法林-4-o-乙酰-gprp,其合成,活性和应用
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
CN108976285B (zh) * 2017-05-31 2021-11-30 首都医科大学 Gly-Pro-Arg-Pro-AA修饰的华法林,其合成,活性和应用
CN108976284B (zh) * 2017-05-31 2021-11-30 首都医科大学 含Gly-Pro-Arg-Pro的五肽修饰的华法林,其合成,活性和应用
ES2832881T3 (es) * 2018-04-24 2021-06-11 Fibriant B V Variantes de fibrinógeno gamma prima para su uso en el tratamiento de una infección
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
CN115010784B (zh) * 2022-05-16 2023-03-31 江南大学 一种ace抑制肽及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107628D0 (en) 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
DE69334033D1 (de) * 1992-05-21 2006-07-27 Diatide Inc Technetium-99M markierte Peptide zur Bilderzeugung von Thrombus
US6184205B1 (en) * 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
ATE217344T1 (de) * 1994-09-21 2002-05-15 Cytogen Corp Antigen bindende peptide (abtides) aus peptidbibliotheken
AU718956B2 (en) * 1996-10-21 2000-05-04 Quadrant Healthcare (Uk) Limited Platelet substitutes and conjugation methods suitable for their preparation
US6264988B1 (en) * 1997-06-05 2001-07-24 Hemosphere, Inc. Fibrinogen-coated microspheres
DK9700423U3 (da) * 1997-11-10 1999-03-12 Simatek A S Multifunktion cip-dyse
US20030021777A1 (en) * 1998-02-20 2003-01-30 Roy Harris Product comprising bound fibrinogen and thrombin for use in wound therapy or surgical repair
GB9827813D0 (en) * 1998-12-17 1999-02-10 Andaris Ltd Pharmaceutical conjugates
US6984373B2 (en) * 2000-12-23 2006-01-10 Dyax Corp. Fibrin binding moieties useful as imaging agents
GB0323378D0 (en) * 2003-10-07 2003-11-05 Univ Leicester Therapeutic agent
GB0413346D0 (en) * 2004-06-15 2004-07-21 Theryte Ltd Treating cancer
GB201201751D0 (en) * 2012-02-01 2012-03-14 Haemostatix Ltd Haemostatic wound dressing

Also Published As

Publication number Publication date
US20090203619A1 (en) 2009-08-13
AU2006274685A1 (en) 2007-02-08
JP2009505964A (ja) 2009-02-12
GB2429153A (en) 2007-02-21
WO2007015107A2 (en) 2007-02-08
US20130029913A1 (en) 2013-01-31
EP2335737A2 (en) 2011-06-22
IL189105A0 (en) 2008-08-07
GB0516091D0 (en) 2005-09-14
EP1919508B1 (en) 2015-02-25
GB2429153C (en) 2019-01-23
WO2007015107A3 (en) 2007-07-26
GB2429153B (en) 2010-03-10
GB0615545D0 (en) 2006-09-13
EP2335737A3 (en) 2013-09-25
EP1919508A2 (en) 2008-05-14
CN101267843A (zh) 2008-09-17

Similar Documents

Publication Publication Date Title
US20130029913A1 (en) Artificial platelets
Pawlowski et al. Platelet microparticle-inspired clot-responsive nanomedicine for targeted fibrinolysis
RU2503464C2 (ru) Биогель
CA2541005C (en) Fibrinogen targetting microparticles for promoting haemostasis
AU2002334266B2 (en) Vascular occlusion solid-phase agent with immobilised platelet binding agent
Chan et al. Synthetic strategies for engineering intravenous hemostats
US20110077202A1 (en) Targeted Coagulation Factors and Method of Using the Same
US9724379B2 (en) Therapeutic agents with improved fibrinogen binding
JP2007507480A5 (cg-RX-API-DMAC10.html)
US20240108748A1 (en) Compositions and methods for targeted amplification of coagulation and phagocytosis
JP2017501217A (ja) 出血性症候群の場合における失血を制御する及び／又は血小板の代用にすることが可能であるコラーゲンに基づいた注射用製剤
WO2000035487A1 (en) Pharmaceutical conjugates comprising two active agents
WO2021155198A1 (en) Nanomaterials for targeted treatment and imaging of aneurysmal microenvironment
MXPA99003677A (en) Platelet substitutes and conjugation methods suitable for their preparation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130806